Macquarie Group LTD Biogen Inc. Transaction History

Macquarie Group LTD

$85.1 Billion
Q2 2024

A detailed history of Macquarie Group LTD transactions in Biogen Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 55,829 shares of BIIB stock, worth $11.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

55,829

Previous 120,721 53.75%

Holding current value

$11.2 Million

Previous $26 Million 50.28%

% of portfolio

0.02%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$190.52 - $236.72 $12.4 Million - $15.4 Million	-64,892 Reduced 53.75%	55,829 $12.9 Million
Q1 2024 May 14, 2024	SELL	$212.02 - $267.71 $28.5 Million - $36 Million	-134,394 Reduced 52.68%	120,721 $26 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $4 Million - $4.82 Million	-17,992 Reduced 6.59%	255,115 $66 Million
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $52.6 Million - $59.4 Million	207,708 Added 317.6%	273,107 $70.2 Million
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $1.67 Million - $1.93 Million	6,059 Added 10.21%	65,399 $18.6 Million
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $1.63 Million - $1.86 Million	6,358 Added 12.0%	59,340 $16.5 Million
Q4 2022 Feb 21, 2023	BUY	$252.44 - $306.72 $220,632 - $268,073	874 Added 1.68%	52,982 $14.7 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $64,053 - $88,323	329 Added 0.64%	52,108 $13.9 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $634,635 - $754,699	-3,384 Reduced 6.13%	51,779 $10.6 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $281,547 - $354,735	-1,453 Reduced 2.57%	55,163 $11.6 Million
Q4 2021 Feb 11, 2022	SELL	$223.92 - $287.77 $3.53 Million - $4.54 Million	-15,769 Reduced 21.78%	56,616 $13.6 Million
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $455,613 - $594,170	1,610 Added 2.27%	72,385 $20.5 Million
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $244,496 - $391,486	944 Added 1.35%	70,775 $24.5 Million
Q1 2021 May 14, 2021	BUY	$242.95 - $284.63 $10,689 - $12,523	44 Added 0.06%	69,831 $19.5 Million
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $166,799 - $251,074	-706 Reduced 1.0%	69,787 $17.1 Million
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $800,929 - $924,772	3,025 Added 4.48%	70,493 $20 Million
Q2 2020 Aug 11, 2020	SELL	$258.66 - $342.55 $17.3 Million - $22.9 Million	-66,904 Reduced 49.79%	67,468 $18.1 Million
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $863,815 - $1.1 Million	3,213 Added 2.45%	134,372 $42.5 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $58.5 Million - $80.8 Million	-265,824 Reduced 66.96%	131,159 $38.9 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $5.95 Million - $6.68 Million	-27,376 Reduced 6.45%	396,983 $92.4 Million
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $14.6 Million - $16 Million	-66,357 Reduced 13.52%	424,359 $99.2 Million
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $40.6 Million - $63.5 Million	-187,375 Reduced 27.63%	490,716 $116 Million
Q4 2018 Feb 15, 2019	SELL	$278.5 - $352.75 $35.3 Million - $44.7 Million	-126,620 Reduced 15.73%	678,091 $204 Million
Q3 2018 Nov 15, 2018	BUY	$293.51 - $383.83 $20.4 Million - $26.7 Million	69,498 Added 9.45%	804,711 $284 Million
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $10.1 Million - $12 Million	39,251 Added 5.64%	735,213 $213 Million
Q1 2018 May 11, 2018	SELL	$260.13 - $367.91 $8.33 Million - $11.8 Million	-32,032 Reduced 4.4%	695,962 $191 Million
Q4 2017 Feb 15, 2018	BUY	$307.64 - $344.58 $9.16 Million - $10.3 Million	29,762 Added 4.26%	727,994 $232 Million
Q3 2017 Nov 08, 2017	BUY	$281.15 - $329.69 $196 Million - $230 Million	698,232	698,232 $219 Million

Others Institutions Holding BIIB

# of Institutions

1,050

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $29B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Biogen Inc. Transaction History